EP1645277A1 — Stable tetrodotoxin freeze drying medicinal preparation
Assigned to Wex Medical Ltd · Expires 2006-04-12 · 20y expired
What this patent protects
The present invention provides a freeze-dried pharmaceutical formulation comprising tetrodotoxin or an analog thereof in an amount of 0.5-60 µg per dose, which has good stability and is safe for use by injection in humans and can be stored at room temperature for a long time. Sai…
USPTO Abstract
The present invention provides a freeze-dried pharmaceutical formulation comprising tetrodotoxin or an analog thereof in an amount of 0.5-60 µg per dose, which has good stability and is safe for use by injection in humans and can be stored at room temperature for a long time. Said formulation also contains compounds, such as compounds containing glucosidic bonds selected from any one of disaccharides, ficolls, the derivatives thereof or their mixtures capable of reducing C-4 hydroxyl activity of the tetrodotoxin molecule or the analogs thereof, and a co-solvent(s) which improves solubility of tetrodotoxin or the analogs thereof.
Drugs covered by this patent
- Tygacil (TIGECYCLINE) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.